{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:26:20Z","timestamp":1792452380700,"version":"4.5.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,14]],"date-time":"2019-07-14T00:00:00Z","timestamp":1563062400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,14]],"date-time":"2019-07-14T00:00:00Z","timestamp":1563062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1038\/s41386-019-0463-z","type":"journal-article","created":{"date-parts":[[2019,7,14]],"date-time":"2019-07-14T11:03:26Z","timestamp":1563102206000},"page":"129-140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Sleep and neurological autoimmune diseases"],"prefix":"10.1038","volume":"45","author":[{"given":"Alex","family":"Iranzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,14]]},"reference":[{"key":"463_CR1","unstructured":"American Academy of Sleep Medicine. International classification of sleep disorders, 3rd edn. Darien, IL: American Academy of Sleep Medicine, 2014."},{"key":"463_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(07)60237-2","volume":"369","author":"Y Dauvilliers","year":"2007","unstructured":"Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369:499\u2013511.","journal-title":"Lancet"},{"key":"463_CR3","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1093\/brain\/awr244","volume":"134","author":"G Plazzi","year":"2011","unstructured":"Plazzi G, Pizza F, Palaia V, et al. Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. Brain. 2011;134:3477\u201389.","journal-title":"Brain"},{"key":"463_CR4","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1073\/pnas.95.1.322","volume":"95","author":"L de Lecea","year":"1998","unstructured":"de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95:322\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"463_CR5","doi-asserted-by":"publisher","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","volume":"18","author":"C Peyron","year":"1998","unstructured":"Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18:9996\u201310015.","journal-title":"J Neurosci"},{"key":"463_CR6","doi-asserted-by":"publisher","first-page":"F1000 Faculty R","DOI":"10.12688\/f1000research.15097.1","volume":"7","author":"N Nevarez","year":"2018","unstructured":"Nevarez N, de Lecea L. Recent advances in understanding the roles of hypocretin\/orexin in arousal, affect, and motivation. F1000Res. 2018;7:F1000 Faculty Rev\u20131421.","journal-title":"F1000Res"},{"key":"463_CR7","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/79690","volume":"6","author":"C Peyron","year":"2000","unstructured":"Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6:991\u20137.","journal-title":"Nat Med"},{"key":"463_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","volume":"355","author":"S Nishino","year":"2000","unstructured":"Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355:39\u201340.","journal-title":"Lancet"},{"key":"463_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1474-4422(08)70140-6","volume":"7","author":"P Bourgin","year":"2008","unstructured":"Bourgin P, Zeitzer JM, Mignot E. CSF hypocretin-1 assessment in sleep and neurological disorders. Lancet Neurol. 2008;7:649\u201362.","journal-title":"Lancet Neurol"},{"key":"463_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","volume":"27","author":"TC Thannickal","year":"2000","unstructured":"Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27:469\u201374.","journal-title":"Neuron"},{"key":"463_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41583-018-0097-x","volume":"20","author":"CE Mahoney","year":"2019","unstructured":"Mahoney CE, Cogswell A, Koralnik IJ, Scammell TE. The neurobiological basis of narcolepsy. Nat Rev Neurosci. 2019;20:83\u201393.","journal-title":"Nat Rev Neurosci"},{"key":"463_CR12","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/sleep\/32.8.979","volume":"32","author":"A Aran","year":"2009","unstructured":"Aran A, Lin L, Nevsimalova S, Plazzi G, Hong SC, Weiner K, et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep. 2009;32:979\u201383.","journal-title":"Sleep"},{"key":"463_CR13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/ana.22587","volume":"70","author":"F Han","year":"2011","unstructured":"Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol. 2011;70:410\u201317.","journal-title":"Ann Neurol"},{"key":"463_CR14","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/S1474-4422(14)70075-4","volume":"13","author":"M Partinen","year":"2014","unstructured":"Partinen M, Kornum BR, Plazzi G, Jennum P, Julkunen I, Vaarala O. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol. 2014;13:600\u201313.","journal-title":"Lancet Neurol"},{"key":"463_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41586-018-0540-1","volume":"562","author":"D Latorre","year":"2018","unstructured":"Latorre D, Kallweit U, Armentani E, et al. T cells in patients with narcolepsy target self-antigens of hypocretin neurons. Nature. 2018;562:63\u201368.","journal-title":"Nature"},{"key":"463_CR16","doi-asserted-by":"publisher","first-page":"e0169836.","DOI":"10.1371\/journal.pone.0169836","volume":"12","author":"M Lecendreux","year":"2017","unstructured":"Lecendreux M, Churlaud G, Pitoiset F, et al. Narcolepsy type 1 is associated with a systemic increase and activation of regulatory t cells and with a systemic activation of global T cells. PLoS ONE. 2017;12:e0169836.","journal-title":"PLoS ONE"},{"key":"463_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08774-1","volume":"10","author":"NW Pedersen","year":"2019","unstructured":"Pedersen NW, Holm A, Kristensen NP, et al. CD8+ T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens. Nat Commun. 2019;10:837.","journal-title":"Nat Commun"},{"key":"463_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/NSS.S103467","volume":"9","author":"VC Abad","year":"2017","unstructured":"Abad VC, Guilleminault C. New developments in the management of narcolepsy. Nat Sci Sleep. 2017;9:39\u201357.","journal-title":"Nat Sci Sleep"},{"key":"463_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11940-016-0429-y","volume":"18","author":"L Barateau","year":"2016","unstructured":"Barateau L, Lopez R, Dauvilliers Y. Management of Narcolepsy. Curr Treat Options Neurol. 2016;18:43.","journal-title":"Curr Treat Options Neurol"},{"key":"463_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jsmc.2018.02.009","volume":"13","author":"GJ Lammers","year":"2018","unstructured":"Lammers GJ. Drugs used in narcolepsy and other hypersomnias. Sleep Med Clin. 2018;13:183\u201389.","journal-title":"Sleep Med Clin"},{"key":"463_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1474-4422(14)70051-1","volume":"13","author":"L Sabater","year":"2014","unstructured":"Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014;13:575\u201386.","journal-title":"Lancet Neurol"},{"key":"463_CR22","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(15)60445-7","volume":"385","author":"B H\u00f6gl","year":"2015","unstructured":"H\u00f6gl B, Heidbreder A, Santamaria J, Graus F, Poewe W. IgLON5 autoimmunity and abnormal behaviours during sleep. Lancet. 2015;385:1590.","journal-title":"Lancet"},{"key":"463_CR23","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1212\/NXI.0000000000000136","volume":"2","author":"MM Simabukuro","year":"2015","unstructured":"Simabukuro MM, Sabater L, Adoni T, et al. Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. Neurol Neuroimmunol Neuroinflamm. 2015;2:e136.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"463_CR24","first-page":"710","volume":"30","author":"MT Montojo","year":"2015","unstructured":"Montojo MT, Piren V, Benkhadra F, et al. Mimicking progressive supranuclear palsy and causing Tako-Tsubo syndrome: a case report on IgLON5 encephalopathy [abstract]. Mov Disord. 2015;30:710.","journal-title":"Mov Disord"},{"key":"463_CR25","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/mds.26608","volume":"31","author":"N Br\u00fcggemann","year":"2016","unstructured":"Br\u00fcggemann N, Wandinger KP, Gaig C, et al. Dystonia, lower limb stiffness, and upward gaze palsy in a patient with IgLON5 antibodies. Mov Disord. 2016;31:762\u201364.","journal-title":"Mov Disord"},{"key":"463_CR26","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1212\/NXI.0000000000000302","volume":"4","author":"JB Schr\u00f6der","year":"2016","unstructured":"Schr\u00f6der JB, Melzer N, Ruck T, et al. Isolated dysphagia as initial sign of anti-IgLON5 syndrome. Neurol Neuroimmunol Neuroinflamm. 2016;4:e302.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"463_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jneuroim.2016.09.012","volume":"300","author":"R Haitao","year":"2016","unstructured":"Haitao R, Yingmai Y, Yan H, et al. Chorea and parkinsonism associated with autoantibodies to IgLON5 and responsive to immunotherapy. J Neuroimmunol. 2016;300:9\u201310.","journal-title":"J Neuroimmunol"},{"key":"463_CR28","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/RLU.0000000000001339","volume":"41","author":"W Zhang","year":"2016","unstructured":"Zhang W, Niu N, Cui R. Serial 18F-FDG PET\/CT findings in a patient with IgLON5 encephalopathy. Clin Nucl Med. 2016;41:787\u201388.","journal-title":"Clin Nucl Med"},{"key":"463_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00401-016-1591-8","volume":"132","author":"E Gelpi","year":"2016","unstructured":"Gelpi E, H\u00f6ftberger R, Graus F, et al. Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol. 2016;132:531\u201343.","journal-title":"Acta Neuropathol"},{"key":"463_CR30","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1212\/WNL.0000000000003887","volume":"88","author":"C Gaig","year":"2017","unstructured":"Gaig C, Graus F, Compta Y, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88:1736\u201343.","journal-title":"Neurology"},{"key":"463_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/JAD-170189","volume":"59","author":"A Cagnin","year":"2017","unstructured":"Cagnin A, Mariotto S, Fiorini M, et al. Microglial and neuronal TDP-43 pathology in anti-IgLON5-related taupathy. J Clin Alzheimer\u2019s Dis. 2017;59:13\u201320.","journal-title":"J Clin Alzheimer\u2019s Dis"},{"key":"463_CR32","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1212\/NXI.0000000000000385","volume":"4","author":"JA Honorat","year":"2017","unstructured":"Honorat JA, Lomorowski L, Josephs KA, et al. IgLON5 antibody. Neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm. 2017;4:e385.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"463_CR33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jneuroim.2014.08.027","volume":"275","author":"R Bahtz","year":"2014","unstructured":"Bahtz R, Teegen B, Borowski K, et al. Autonatibodies against IgLON5: two new cases. J Neuroimmunol. 2014;275:8.","journal-title":"J Neuroimmunol"},{"key":"463_CR34","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1212\/NXI.0000000000000383","volume":"4","author":"M Bonello","year":"2017","unstructured":"Bonello M, Jacob A, Ellul MA, et al. IgLON5 disease responsive to immunotherapy. Neurol Neuroimmunol Neuroinflamm. 2017;4:e383.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"463_CR35","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JND-170259","volume":"4","author":"S Wenninger","year":"2017","unstructured":"Wenninger S. Expanding the cinical spectrum of IgLON5-syndrome. J Neuromuscul Dis. 2017;4:337\u201339.","journal-title":"J Neuromuscul Dis"},{"key":"463_CR36","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fneur.2018.00329","volume":"9","author":"M Montagna","year":"2018","unstructured":"Montagna M, Amir R, De Volder I, Lammens M, Huyskens J, Willekens B. IgLON5-associated encephalitis with atypical brain magnetic resonance imaging and cerebrospinal fluid changes. Front Neurol 2018;9:329.","journal-title":"Front Neurol"},{"key":"463_CR37","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/cns.13038","volume":"24","author":"QQ Tao","year":"2018","unstructured":"Tao QQ, Wei Q, Song SJ, Yin XZ. Motor neuron disease-like phenotype associated with anti-IgLON5 disease. CNS Neurosci Ther. 2018;24:1305\u201308.","journal-title":"CNS Neurosci Ther"},{"key":"463_CR38","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1212\/NXI.0000000000000485","volume":"5","author":"VK Ramanan","year":"2018","unstructured":"Ramanan VK, Crum BA, McKeon A. Subacute encephalitis with recovery in IgLON5 autoimmunity. Neurol Neuroimmunol Neuroinflamm. 2018;5:e485.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"463_CR39","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/mdc3.12679","volume":"5","author":"A Moreno-Est\u00e9banez","year":"2018","unstructured":"Moreno-Est\u00e9banez A, Garcia-Ormaechea M, Tijero B, et al. Anti-IgLON5 disease responsive to immunotherapy: a case report with an abnormal MRI. Mov Disord Clin Pr. 2018;5:653\u201356.","journal-title":"Mov Disord Clin Pr"},{"key":"463_CR40","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1212\/WNL.0000000000005679","volume":"90","author":"H Morales-Brice\u00f1o","year":"2018","unstructured":"Morales-Brice\u00f1o H, Cruse B, Fois AF, et al. IgLON5-mediated neurodegeneration is a differential diagnosis of CNS Whipple disease. Neurology. 2018;90:1113\u201315.","journal-title":"Neurology"},{"key":"463_CR41","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1212\/WNL.0000000000005859","volume":"91","author":"F Sch\u00f6berl","year":"2018","unstructured":"Sch\u00f6berl F, Levin J, Remi J, et al. IgLON5: a case with predominant cerebellar tau deposits and leptomeningeal inflammation. Neurology. 2018;91:180\u201382.","journal-title":"Neurology"},{"key":"463_CR42","doi-asserted-by":"publisher","first-page":"e1659","DOI":"10.1212\/WNL.0000000000006388","volume":"91","author":"E Vetter","year":"2018","unstructured":"Vetter E, Olmes DG, Linker R, Seifert F. Teaching video neuroImages: facial myokymia and myorhythmia in anti-IgLON5 disease: The bitten lip. Neurology. 2018;91:e1659.","journal-title":"Neurology"},{"key":"463_CR43","doi-asserted-by":"publisher","unstructured":"Logmin K, Moldovan AS, Elben S, Schnitzler A, Groiss SJ Intravenous immunoglobulins as first-line therapy for IgLON5 encephalopathy. J Neurol 2019. \nhttps:\/\/doi.org\/10.1007\/s00415-019-09221-3\n\n.","DOI":"10.1007\/s00415-019-09221-3"},{"key":"463_CR44","doi-asserted-by":"publisher","unstructured":"Gaig C, Compta Y Neurological profiles beyond the sleep disorder in patients with anti-IgLON5 disease. Curr Opin Neurol 2019. \nhttps:\/\/doi.org\/10.1097\/WCO.0000000000000677\n\n.","DOI":"10.1097\/WCO.0000000000000677"},{"key":"463_CR45","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1111\/ene.13566","volume":"25","author":"K Hasselbacher","year":"2018","unstructured":"Hasselbacher K, Steffen A, Wandinger KP, Br\u00fcggemann N. IgLON5 antibodies are infrequent in patients with isolated sleep apnea. Eur J Neurol. 2018;25:e46\u2013e47. \nhttps:\/\/doi.org\/10.1111\/ene.13566\n\n.","journal-title":"Eur J Neurol"},{"key":"463_CR46","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.parkreldis.2017.03.002","volume":"38","author":"S Mangesius","year":"2017","unstructured":"Mangesius S, Sprenger F, H\u00f6ftberger R, Seppi K, Reindl M, Poewe W. IgLON5 autoimmunity tested negative in patients with progressive supranuclear palsy and corticobasal syndrome. Park Relat Disord. 2017;38:102\u201303.","journal-title":"Park Relat Disord"},{"key":"463_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11940-018-0515-4","volume":"20","author":"A Heidbreder","year":"2018","unstructured":"Heidbreder A, Philipp K. Anti-IgLON 5 Disease. Curr Treat Options Neurol. 2018;20:29","journal-title":"Curr Treat Options Neurol"},{"key":"463_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0689-1","volume":"13","author":"L Sabater","year":"2016","unstructured":"Sabater L, Planagum\u00e0 J, Dalmau J, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflamm. 2016;13:226. \nhttps:\/\/doi.org\/10.1186\/s12974-016-0689-1\n\n.","journal-title":"J Neuroinflamm"},{"key":"463_CR49","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1212\/01.WNL.0000036605.89977.D0","volume":"59","author":"Y Dauvilliers","year":"2002","unstructured":"Dauvilliers Y, Mayer G, Lecendreux M, et al. Kleine-Levin syndrome: an autoimmune hypothesis based on clinical and genetic analyses. Neurology. 2002;59:1739\u201345.","journal-title":"Neurology"},{"key":"463_CR50","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jns.2011.07.015","volume":"309","author":"A Caminero","year":"2011","unstructured":"Caminero A, Bartolom\u00e9 M. Sleep disturbances in multiple sclerosis. J Neurol Sci. 2011;309:86\u201391.","journal-title":"J Neurol Sci"},{"key":"463_CR51","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40675-017-0092-1","volume":"3","author":"TJ Braley","year":"2017","unstructured":"Braley TJ. Overview: a framework for the discussion of sleep in multiple sclerosis. Curr Sleep Med Rep. 2017;3:263\u201371.","journal-title":"Curr Sleep Med Rep"},{"key":"463_CR52","doi-asserted-by":"crossref","unstructured":"Foschi M, Rizzo G, Liguori R, et al. Sleep-related disorders and their relationship with MRI findings in multiple sclerosis. Sleep Med. 2019;56: 90\u201397.","DOI":"10.1016\/j.sleep.2019.01.010"},{"key":"463_CR53","doi-asserted-by":"publisher","first-page":"4.","DOI":"10.1007\/s11940-019-0544-7","volume":"21","author":"GK Sakkas","year":"2019","unstructured":"Sakkas GK, Giannaki CD, Karatzaferi C, Manconi M. Sleep abnormalities in multiple sclerosis. Curr Treat Options Neurol. 2019;21:4.","journal-title":"Curr Treat Options Neurol"},{"key":"463_CR54","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1177\/1352458506074644","volume":"13","author":"M Gomez-Choco","year":"2007","unstructured":"Gomez-Choco M, Iranzo A, Blanco Y, Graus F, Santamaria J, Saiz A. Prevalence of restless legs syndrome and REM sleep behavior disorder in. Mult Scler Mult Scler. 2007;13:805\u201308.","journal-title":"Mult Scler Mult Scler"},{"key":"463_CR55","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1389-9457(02)00042-4","volume":"3","author":"G Plazzi","year":"2002","unstructured":"Plazzi G, Montagna P, Remitting REM. sleep behaviour disorder as the initial sign of multiple sclerosis. Sleep Med. 2002;3:437\u201339.","journal-title":"Sleep Med"},{"key":"463_CR56","doi-asserted-by":"publisher","first-page":"180","DOI":"10.7224\/1537-2073.2017-001","volume":"20","author":"A Enriquez-Marulanda","year":"2018","unstructured":"Enriquez-Marulanda A, Quintana-Pe\u00f1a, Takeuchi Y, Qui\u00f1ones J. Rapid eye movement sleep behavior disorder as the first manifestation of multiple sclerosis. A case report and literature review. Int J MS Care. 2018;20:180\u201384.","journal-title":"Int J MS Care"},{"key":"463_CR57","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1212\/01.wnl.0000208518.72660.ff","volume":"66","author":"M Tippmann-Peikert","year":"2006","unstructured":"Tippmann-Peikert M, Boeve BF, Keegan BM. REM sleep behavior disorder initiated by acute brainstem multiple sclerosis. Neurology. 2006;66:1277\u201379.","journal-title":"Neurology"},{"key":"463_CR58","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1212\/01.WNL.0000081049.14098.50","volume":"61","author":"S Nishino","year":"2003","unstructured":"Nishino S, Kanbayashi T, Fujiki N, et al. CSF hypocretin in Guillain-Barr\u00e9 syndrome and other inflammatory neuropathies. Neurology. 2003;61:823\u201325.","journal-title":"Neurology"},{"key":"463_CR59","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1600-0404.2012.01688.x","volume":"127","author":"K Karkare","year":"2013","unstructured":"Karkare K, Sinha S, Taly AB, Rao S. Prevalence and profile of sleep disturbances in Guillain-Barre Syndrome: a prospective questionnaire-based study during 10 days of hospitalization. Acta Neurol Scand. 2013;127:116\u201323.","journal-title":"Acta Neurol Scand"},{"key":"463_CR60","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3109\/00207454.2015.1080699","volume":"126","author":"J Gao","year":"2016","unstructured":"Gao J, Li Y, Sun Y, Hu W, Liu Y, An D, et al. The study of sleep disorder factors in patients with Guillain-Barr\u00e9 syndrome. Int J Neurosci. 2016;126:893\u201398.","journal-title":"Int J Neurosci"},{"key":"463_CR61","doi-asserted-by":"publisher","first-page":"5.","DOI":"10.1186\/s41983-018-0007-1","volume":"54","author":"WS Bahnasy","year":"2018","unstructured":"Bahnasy WS, El-Heneedy YAE, El-Shamy AM, Badr MY, Amer RA, Ibrahim ISE. Sleep and psychiatric abnormalities in Gullian Barr\u00e9 Syndrome. Egypt J Neurol Psychiatr Neurosurg. 2018;54:5.","journal-title":"Egypt J Neurol Psychiatr Neurosurg"},{"key":"463_CR62","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1093\/brain\/awh585","volume":"128","author":"V Cochen","year":"2005","unstructured":"Cochen V, Arnulf I, Demeret S, et al. Vivid dreams, hallucinations, psychosis and REM sleep in Guillain-Barr\u00e9 syndrome. Brain. 2005;128:2535\u201345.","journal-title":"Brain"},{"key":"463_CR63","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ncl.2018.04.015","volume":"36","author":"MR Rosenfeld","year":"2018","unstructured":"Rosenfeld MR, Dalmau J. Paraneoplastic neurologic syndromes. Neurol Clin. 2018;36:675\u201385.","journal-title":"Neurol Clin"},{"key":"463_CR64","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/CCO.0000000000000222","volume":"27","author":"R H\u00f6ftenberfg","year":"2015","unstructured":"H\u00f6ftenberfg R, Rosenfeld M, Dalmau J. Update on neurological paraneoplastic syndromes. Curr Opin Oncol. 2015;27:489\u201395.","journal-title":"Curr Opin Oncol"},{"key":"463_CR65","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/B978-0-444-63432-0.00018-9","volume":"133","author":"MH Silber","year":"2016","unstructured":"Silber MH. Autoimmune sleep disorders. Handb Clin Neurol. 2016;133:317\u201326.","journal-title":"Handb Clin Neurol"},{"key":"463_CR66","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/brain\/awh203","volume":"127","author":"J Dalmau","year":"2004","unstructured":"Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain. 2004;127:1831\u201344.","journal-title":"Brain"},{"key":"463_CR67","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1212\/01.wnl.0000223647.83708.20","volume":"67","author":"DT Blumenthal","year":"2006","unstructured":"Blumenthal DT, Salzman KL, Digre KB, Jensen RL, Dunson WA, Dalmau J. Early pathologic findings and long-term improvement in anti-Ma2-associated encephalitis. Neurology. 2006;67:146\u201349.","journal-title":"Neurology"},{"key":"463_CR68","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1212\/01.WNL.0000101718.92619.67","volume":"62","author":"S Overeem","year":"2004","unstructured":"Overeem S, Dalmau J, Bataller L, et al. HCRT-1 CSF levels in anti-Ma2 associated encephalitis. Neurology. 2004;62:138\u201340.","journal-title":"Neurology"},{"key":"463_CR69","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1136\/jnnp.2007.118588","volume":"79","author":"LA Hoffmann","year":"2008","unstructured":"Hoffmann LA, Jarious S, Pellkofer HL, et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry. 2008;79:767\u201373.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"463_CR70","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1215\/S1152851702000467","volume":"5","author":"JC Landolfi","year":"2003","unstructured":"Landolfi JC, Nadkarni M. Paraneoplastic limbic encephalitis and possible narcolepsy in a patient with testicular cancer: case study. Neuro-Oncol. 2003;5:214\u201316.","journal-title":"Neuro-Oncol"},{"key":"463_CR71","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/sleep\/30.6.767","volume":"30","author":"Y Compta","year":"2007","unstructured":"Compta Y, Iranzo A, Santamaria J, Casamitjana R, Graus F. REM sleep behavior disorder and narcolpetic features in anti-Ma2 encephalitis. Sleep. 2007;30:767\u201369.","journal-title":"Sleep"},{"key":"463_CR72","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1215\/15228517-2006-013","volume":"9","author":"I Rojas-Marcos","year":"2007","unstructured":"Rojas-Marcos I, Graus F, Sanz G, Robledo A, Diaz-Espejo C. Hypersomnia as presenting symptom of anti-Ma2-associated encephalitis: case study. Neuro-Oncol. 2007;9:75\u201377.","journal-title":"Neuro-Oncol"},{"key":"463_CR73","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1136\/jnnp.74.9.1332","volume":"74","author":"K Sahashi","year":"2003","unstructured":"Sahashi K, Sakai K, Mano K, Hirose G. Anti-Ma2 related paraneoplastic limbic\/brain stem encephalitis associated with breast cancer expressing Ma1, Ma2, and Ma3 mRNAs. J Neurol Neurosurg Psychiatry. 2003;74:1332\u201335.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"463_CR74","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1212\/WNL.52.4.864","volume":"52","author":"JL Bennet","year":"1999","unstructured":"Bennet JL, Galetta SL, Frohman LP, et al. Neuro-opthalamic manifestations of a paraneoplastic syndrome and testicular carcinoma. Neurology. 1999;52:864\u201367.","journal-title":"Neurology"},{"key":"463_CR75","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/jnnp.2005.068775","volume":"77","author":"M Waragai","year":"2006","unstructured":"Waragai M, Chiba A, Uchibori A, Fukushima T, Anno A, Tanaka K. Anti-Ma2 associated paarneoplastic neurological syndrome presenting as encephalitis and progressive muscular atrophy. J Neurol Neurosurg Psychiatry. 2006;77:111\u201313.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"463_CR76","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1212\/01.WNL.0000085873.45099.E2","volume":"61","author":"R Scheid","year":"2003","unstructured":"Scheid R, Voltz R, Guthke T, Sammler D, von Crammon DY. Neuropsychiatric findings in anti-Ma2-positive paraneoplastic limbic encephalitis. Neurology. 2003;61:1159\u201360.","journal-title":"Neurology"},{"key":"463_CR77","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1136\/jnnp.69.2.266","volume":"69","author":"I Sutton","year":"2000","unstructured":"Sutton I, Winner J, Rowlands D, Dalmau J. Limbic encephalitis and antibodies to Ma2: a paraneoplastic presentation of breast cancer. J Neurol Neurosurg Psychiatry. 2000;69:266\u201368.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"463_CR78","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/jnnp.70.2.222","volume":"70","author":"M Barnett","year":"2001","unstructured":"Barnett M, Prosser J, Sutton I, et al. Paraneoplastic brain stem encephalitis in a woman with anti-Ma2 antibody. J Neurol Neurosurg Psychiatry. 2001;70:222\u201325.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"463_CR79","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/archneurol.2011.56","volume":"68","author":"C Adams","year":"2011","unstructured":"Adams C, McKeon A, Silber MH, Kumar R. Narcolepsy, REM sleep behavior disorder, and supranuclear gaze palsy associated with Ma1 and Ma2 antibodies and tonsillar carcinoma. Arch Neurol. 2011;68:521\u201324.","journal-title":"Arch Neurol"},{"key":"463_CR80","first-page":"1305","volume":"70","author":"Y Dauvilliers","year":"2013","unstructured":"Dauvilliers Y, Bauer J, Rigau V. Hypothalamic immunopathologyin anti-Ma-associated diencephalitis with narcolepsy-cataplexy. JAMA Neurol. 2013;70:1305\u201310.","journal-title":"JAMA Neurol"},{"key":"463_CR81","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1016\/j.biopsych.2016.12.014","volume":"83","author":"I Kritikou","year":"2018","unstructured":"Kritikou I, Vgontzas AN, Rapp MA, Bixler EO. Anti-Ma1- and Anti-Ma2-associated encephalitis manifesting with rapid eye movement sleep disorder and narcolepsy with cataplexy: a case report. Biol Psychiatry. 2018;83:e39\u201340.","journal-title":"Biol Psychiatry"},{"key":"463_CR82","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1093\/brain\/awq213","volume":"133","author":"SR Irani","year":"2010","unstructured":"Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010;133:2734\u2013274.","journal-title":"Brain"},{"key":"463_CR83","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ana.20693","volume":"59","author":"A Iranzo","year":"2006","unstructured":"Iranzo A, Graus F, Clover L, et al. Rapid eye movement sleep behavior disorder and potassium channel antibody\u2013associated limbic encephalitis. Ann Neurol. 2006;59:178\u201382.","journal-title":"Ann Neurol"},{"key":"463_CR84","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1001\/archneurol.2011.106","volume":"68","author":"JR Cornellius","year":"2011","unstructured":"Cornellius JR, Pittock SJ, McKeom A, et al. Sleep manifestations of voltage-gated potassium channel complex autoimmunity. Arch Neurol. 2011;68:733\u201338.","journal-title":"Arch Neurol"},{"key":"463_CR85","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1001\/archneur.69.1.145","volume":"69","author":"I Tezer","year":"2012","unstructured":"Tezer I, Erdener E, Sel CC, Mendikanova L, Sagy S, Topcuoglu M. Daytime polysomnography recording in LIG1-related limbic encephalitis. Arch Neurol. 2012;69:145\u201346.","journal-title":"Arch Neurol"},{"key":"463_CR86","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/nyas.12553","volume":"1338","author":"F Leypoldt","year":"2015","unstructured":"Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann N Y Acad Sci. 2015;1338:94\u2013114.","journal-title":"Ann N Y Acad Sci"},{"key":"463_CR87","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/smrv.2001.0166","volume":"5","author":"E Lugaresi","year":"2001","unstructured":"Lugaresi E, Provini F. Agrypnia excitata: clinical features and pathophysiological implications. Sleep Med Rev. 2001;5:313\u201322.","journal-title":"Sleep Med Rev"},{"key":"463_CR88","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1093\/brain\/124.12.2417","volume":"124","author":"R Liguori","year":"2001","unstructured":"Liguori R, Vincent A, Clover L, Avoni P, Plazzi G, Cortelli P, et al. Morvan\u2019s Syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain. 2001;124:2417\u201326.","journal-title":"Brain"},{"key":"463_CR89","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/j.sleep.2011.10.014","volume":"12","author":"P Guaraldi","year":"2011","unstructured":"Guaraldi P, Calandra-Buonaura G, Terlizzi R, et al. Oneiric stupor: the peculiar behaviour of agrypnia excitata. Sleep Med. 2011;12:S64\u201367.","journal-title":"Sleep Med"},{"key":"463_CR90","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.sleep.2011.05.005","volume":"12","author":"P Provini","year":"2011","unstructured":"Provini P, Marconi M, Amadori M, et al. Morvan chorea and agrypnia excitata: when video-polysomnographic recording guides the diagnosis. Sleep Med. 2011;12:1041\u201343.","journal-title":"Sleep Med"},{"key":"463_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.smrv.2015.07.003","volume":"28","author":"E Antelmi","year":"2016","unstructured":"Antelmi E, Ferri R, Iranzo A, et al. From state dissociation to status dissociatus. Sleep Med Rev. 2016;28:1\u201313.","journal-title":"Sleep Med Rev"},{"key":"463_CR92","doi-asserted-by":"publisher","first-page":"117","DOI":"10.5665\/sleep.5330","volume":"39","author":"T Vale","year":"2016","unstructured":"Vale T, Bizari Fernanes do Prado L, Fernnades Do Prado G, Grazian Povoas Barsittini O, Pedroso JL. Rapid eye movement sleep behavior disorder in paraneoplastic cerebellar degeneration: improvement with immunotherapy. Sleep. 2016;39:117\u201320.","journal-title":"Sleep"},{"key":"463_CR93","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1212\/01.wnl.0000168864.97813.e0","volume":"65","author":"A Iranzo","year":"2005","unstructured":"Iranzo A, Santamaria J, Rye DB, et al. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology. 2005;65:247\u201352.","journal-title":"Neurology"},{"key":"463_CR94","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/mds.10509","volume":"18","author":"A Iranzo","year":"2003","unstructured":"Iranzo A, Mu\u00f1oz E, Santamar\u00eda J, Vilaseca I, Mil\u00e0 M, Tolosa E. REM sleep behavior disorder and vocal cord paralysis in Machado-Joseph disease. Mov Disord. 2003;18:1179\u201383.","journal-title":"Mov Disord"},{"key":"463_CR95","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","volume":"10","author":"J Dalmau","year":"2011","unstructured":"Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfield MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63\u201374.","journal-title":"Lancet Neurol"},{"key":"463_CR96","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","volume":"7","author":"J Dalmau","year":"2008","unstructured":"Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091\u201398.","journal-title":"Lancet Neurol"},{"key":"463_CR97","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0896-6273(94)90350-6","volume":"13","author":"D Forrest","year":"1994","unstructured":"Forrest D, Yuzaki M, Soares HD, et al. Targeted disruption of the NMDA receptor 1 gene abolishes NMDA response and results in neuronal death. Neuron. 1994;13:325\u201338.","journal-title":"Neuron"},{"key":"463_CR98","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/mds.25072","volume":"27","author":"M Stamelou","year":"2012","unstructured":"Stamelou M, Plazzi G, Lugaresi E, Edwards MJ, Bathia KP. The distinct movement disorder in anti-NMDA receptor encephalitis may be related to status dissociates: a hypothesis. Mov Disord. 2012;27:1360\u201363.","journal-title":"Mov Disord"},{"key":"463_CR99","doi-asserted-by":"publisher","first-page":"935379","DOI":"10.1155\/2014\/935379","volume":"2014","author":"A Coban","year":"2014","unstructured":"Coban A, K\u00fcc\u00fckali CI, Yalcinkaya N, et al. Evaluation of incidence and clinical features of antibody-associated autoimmune encephalitis mimicking dementia. Behav Neurol. 2014;2014:935379.","journal-title":"Behav Neurol"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41386-019-0463-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-019-0463-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-019-0463-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:06:54Z","timestamp":1684616814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-019-0463-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,14]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["463"],"URL":"https:\/\/doi.org\/10.1038\/s41386-019-0463-z","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,14]]},"assertion":[{"value":"3 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}